📰 Primary Endpoint News
Page 3 - Primary Endpoint News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Primary Endpoint. Real-time updates on events, politics, business and more.
June 28, 2023
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed
June 27, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to patients with chronic cough. The company plans to discuss these results with regulatory authorities while considering expanding clinical testing to include patients with frequent coughing and active inflammation. The Phase 2 trial included 51 patients suffering from refractory or unexplained chronic cough that persists for more t...
June 15, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica
June 7, 2023
Resynchronization therapy jumps forward with 3 new studies that support but push the envelope of a new guideline statement on physiologic pacing for heart failure.
June 4, 2023
- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate
May 17, 2023
Ligand Pharmaceuticals Incorporated announced that its partner Viking Therapeutics, Inc. announced positive top-line results from its Phase 2b clinical trial of VOYAGE, a novel liver-selective thyroid... | May 17, 2023
May 4, 2023
Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37 Plaintiff Esperion Therapeutics, Inc. , by its attorneys, Gibson, Dunn &... | May 4, 2023
May 3, 2023
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023
May 3, 2023
First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million -- -- TEPEZZA® Net Sales of $405.3 Million -- --... | May 3, 2023
April 10, 2023
-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had... | April 10, 2023